Resistell AG

Basel-LResistell is a clinical-stage company developing the world’s fastest Antibiotic Susceptibility Testing (AST) Platform. Resistell has a CE IVD-certified AST in bloodstream infections (BSI) with a time-to-result of 4 hours, tested on 260 patients in two clinical studies across three hospitals. The method shows over 95% accuracy with the gold standard for AST. The 2nd generation device enabling an ultra-rapid AST of only 2 hours is already available. Resistell has recently started sales of a globally certified research device. Resistell has raised CHF 14.6M in equity and CHF 4M from grants so far. We are currently raising funds for the development of a high-throughput diagnostic device based on cutting-edge, highly de-risked, and patented nanomotion technology.